{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:08:29Z","timestamp":1781334509525,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autotaxin (ATX) is a secreted enzyme metabolized by liver sinusoidal endothelial cells that has been associated with liver fibrosis. We evaluated serum ATX values in 128 treatment-na\u00efve, histologically assessed primary biliary cholangitis (PBC) patients and 80 healthy controls for comparisons of clinical parameters in a case-control study. The median ATX concentrations in controls and PBC patients of Nakanuma\u2019s stage I, II, III, and IV were 0.70, 0.80, 0.87, 1.03, and 1.70\u2009mg\/L, respectively, which increased significantly with disease stage (r\u2009=\u20090.53, P\u2009&lt;\u20090.0001) as confirmed by Scheuer\u2019s classification (r\u2009=\u20090.43, P\u2009&lt;\u20090.0001). ATX correlated with <jats:italic>Wisteria floribunda<\/jats:italic> agglutinin-positive Mac-2 binding protein (M2BPGi) (r\u2009=\u20090.51, P\u2009&lt;\u20090.0001) and fibrosis index based on four factors (FIB-4) index (r\u2009=\u20090.51, P\u2009&lt;\u20090.0001). While ALP and M2BPGi levels had decreased significantly (both P\u2009&lt;\u20090.001) by 12 months of ursodeoxycholic acid treatment, ATX had not (0.95 to 0.96\u2009mg\/L) (P\u2009=\u20090.07). We observed in a longitudinal study that ATX increased significantly (P\u2009&lt;\u20090.00001) over 18 years in an independent group of 29 patients. Patients succumbing to disease-related death showed a significantly higher ATX increase rate (0.05\u2009mg\/L\/year) than did survivors (0.02\u2009mg\/L\/year) (P\u2009&lt;\u20090.01). ATX therefore appears useful for assessing disease stage and prognosis in PBC.<\/jats:p>","DOI":"10.1038\/s41598-018-26531-0","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T14:20:45Z","timestamp":1526912445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis"],"prefix":"10.1038","volume":"8","author":[{"given":"Satoru","family":"Joshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-919X","authenticated-orcid":false,"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"26531_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMra043898","volume":"353","author":"MM Kaplan","year":"2005","unstructured":"Kaplan, M. M. & Gershwin, M. E. Primary biliary cirrhosis. N Engl J Med 353, 1261\u20131273, https:\/\/doi.org\/10.1056\/NEJMra043898 (2005).","journal-title":"N Engl J Med"},{"key":"26531_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/gast.2000.20197","volume":"119","author":"WR Kim","year":"2000","unstructured":"Kim, W. R. et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119, 1631\u20131636 (2000).","journal-title":"Gastroenterology"},{"key":"26531_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jhep.2010.03.017","volume":"53","author":"S Joshita","year":"2010","unstructured":"Joshita, S. et al. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. Journal of hepatology 53, 537\u2013541, https:\/\/doi.org\/10.1016\/j.jhep.2010.03.017 (2010).","journal-title":"Journal of hepatology"},{"key":"26531_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep29770","volume":"6","author":"T Umemura","year":"2016","unstructured":"Umemura, T. et al. Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. Scientific reports 6, 29770, https:\/\/doi.org\/10.1038\/srep29770 (2016).","journal-title":"Scientific reports"},{"key":"26531_CR5","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","volume":"360","author":"GM Hirschfield","year":"2009","unstructured":"Hirschfield, G. M. et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. The New England journal of medicine 360, 2544\u20132555, https:\/\/doi.org\/10.1056\/NEJMoa0810440 (2009).","journal-title":"The New England journal of medicine"},{"key":"26531_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/ng.627","volume":"42","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature genetics 42, 658\u2013660, https:\/\/doi.org\/10.1038\/ng.627 (2010).","journal-title":"Nature genetics"},{"key":"26531_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ng.789","volume":"43","author":"GF Mells","year":"2011","unstructured":"Mells, G. F. et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nature genetics 43, 329\u2013332, https:\/\/doi.org\/10.1038\/ng.789 (2011).","journal-title":"Nature genetics"},{"key":"26531_CR8","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1093\/hmg\/dds359","volume":"21","author":"BD Juran","year":"2012","unstructured":"Juran, B. D. et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human molecular genetics 21, 5209\u20135221, https:\/\/doi.org\/10.1093\/hmg\/dds359 (2012).","journal-title":"Human molecular genetics"},{"key":"26531_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ajhg.2012.08.010","volume":"91","author":"M Nakamura","year":"2012","unstructured":"Nakamura, M. et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. American journal of human genetics 91, 721\u2013728, https:\/\/doi.org\/10.1016\/j.ajhg.2012.08.010 (2012).","journal-title":"American journal of human genetics"},{"key":"26531_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/hmg\/ddw406","volume":"26","author":"M Kawashima","year":"2017","unstructured":"Kawashima, M. et al. Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Human molecular genetics 26, 650\u2013659, https:\/\/doi.org\/10.1093\/hmg\/ddw406 (2017).","journal-title":"Human molecular genetics"},{"key":"26531_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/hep.22042","volume":"47","author":"ME Gershwin","year":"2008","unstructured":"Gershwin, M. E. & Mackay, I. R. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 47, 737\u2013745, https:\/\/doi.org\/10.1002\/hep.22042 (2008).","journal-title":"Hepatology"},{"key":"26531_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJM198905253202104","volume":"320","author":"J Van de Water","year":"1989","unstructured":"Van de Water, J. et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. The New England journal of medicine 320, 1377\u20131380, https:\/\/doi.org\/10.1056\/nejm198905253202104 (1989).","journal-title":"The New England journal of medicine"},{"key":"26531_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology (Baltimore, Md.) 50, 291\u2013308, https:\/\/doi.org\/10.1002\/hep.22906 (2009).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR14","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of hepatology 67, 145\u2013172, https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022 (2017).","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"26531_CR15","doi-asserted-by":"publisher","unstructured":"Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatology research: the official journal of the Japan Society of Hepatology 44 Suppl S1, 71\u201390, https:\/\/doi.org\/10.1111\/hepr.12270 (2014).","DOI":"10.1111\/hepr.12270"},{"key":"26531_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jhep.2014.07.036","volume":"61","author":"S Joshita","year":"2014","unstructured":"Joshita, S., Umemura, T., Ota, M. & Tanaka, E. AST\/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. Journal of hepatology 61, 1443\u20131445, https:\/\/doi.org\/10.1016\/j.jhep.2014.07.036 (2014).","journal-title":"Journal of hepatology"},{"key":"26531_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ajg.2015.118","volume":"110","author":"T Umemura","year":"2015","unstructured":"Umemura, T. et al. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. The American journal of gastroenterology 110, 857\u2013864, https:\/\/doi.org\/10.1038\/ajg.2015.118 (2015).","journal-title":"The American journal of gastroenterology"},{"key":"26531_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology (Baltimore, Md.) 48, 871\u2013877, https:\/\/doi.org\/10.1002\/hep.22428 (2008).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura, M. et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology (Baltimore, Md.) 45, 118\u2013127, https:\/\/doi.org\/10.1002\/hep.21472 (2007).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.24705","volume":"55","author":"T Umemura","year":"2012","unstructured":"Umemura, T. et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology (Baltimore, Md.) 55, 506\u2013511, https:\/\/doi.org\/10.1002\/hep.24705 (2012).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11148-6","volume":"7","author":"M Yasunami","year":"2017","unstructured":"Yasunami, M. et al. Principal contribution of HLA-DQ alleles, DQB1*06:04 and DQB1*03:01, to disease resistance against primary biliary cholangitis in a Japanese population. Scientific reports 7, 11093, https:\/\/doi.org\/10.1038\/s41598-017-11148-6 (2017).","journal-title":"Scientific reports"},{"key":"26531_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo, A. A., Sheth, S. G. & Chopra, S. Liver biopsy. The New England journal of medicine 344, 495\u2013500, https:\/\/doi.org\/10.1056\/nejm200102153440706 (2001).","journal-title":"The New England journal of medicine"},{"key":"26531_CR23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","volume":"142","author":"L Castera","year":"2012","unstructured":"Castera, L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142, 1293\u20131302.e1294, https:\/\/doi.org\/10.1053\/j.gastro.2012.02.017 (2012).","journal-title":"Gastroenterology"},{"key":"26531_CR24","doi-asserted-by":"publisher","unstructured":"Ichikawa, Y. et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatology research: the official journal of the Japan Society of Hepatology, https:\/\/doi.org\/10.1111\/hepr.12712 (2016).","DOI":"10.1111\/hepr.12712"},{"key":"26531_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep01065","volume":"3","author":"A Kuno","year":"2013","unstructured":"Kuno, A. et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Scientific reports 3, 1065, https:\/\/doi.org\/10.1038\/srep01065 (2013).","journal-title":"Scientific reports"},{"key":"26531_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00535-014-0946-y","volume":"50","author":"T Toshima","year":"2015","unstructured":"Toshima, T. et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)\u2212M2BP), for assessing liver fibrosis. J Gastroenterol 50, 76\u201384, https:\/\/doi.org\/10.1007\/s00535-014-0946-y (2015).","journal-title":"J Gastroenterol"},{"key":"26531_CR27","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","volume":"60","author":"PJ Trivedi","year":"2014","unstructured":"Trivedi, P. J. et al. Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of hepatology 60, 1249\u20131258, https:\/\/doi.org\/10.1016\/j.jhep.2014.01.029 (2014).","journal-title":"Journal of hepatology"},{"key":"26531_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology (Baltimore, Md.) 43, 1317\u20131325, https:\/\/doi.org\/10.1002\/hep.21178 (2006).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR29","doi-asserted-by":"publisher","first-page":"39436","DOI":"10.1074\/jbc.M205623200","volume":"277","author":"A Tokumura","year":"2002","unstructured":"Tokumura, A. et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. The Journal of biological chemistry 277, 39436\u201339442, https:\/\/doi.org\/10.1074\/jbc.M205623200 (2002).","journal-title":"The Journal of biological chemistry"},{"key":"26531_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1083\/jcb.200204026","volume":"158","author":"M Umezu-Goto","year":"2002","unstructured":"Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of cell biology 158, 227\u2013233, https:\/\/doi.org\/10.1083\/jcb.200204026 (2002).","journal-title":"The Journal of cell biology"},{"key":"26531_CR31","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/S0021-9258(18)45911-X","volume":"267","author":"ML Stracke","year":"1992","unstructured":"Stracke, M. L. et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. The Journal of biological chemistry 267, 2524\u20132529 (1992).","journal-title":"The Journal of biological chemistry"},{"key":"26531_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cca.2011.03.014","volume":"412","author":"H Nakagawa","year":"2011","unstructured":"Nakagawa, H. et al. Autotaxin as a novel serum marker of liver fibrosis. Clinica chimica acta; international journal of clinical chemistry 412, 1201\u20131206, https:\/\/doi.org\/10.1016\/j.cca.2011.03.014 (2011).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"26531_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/bbrc.1998.8983","volume":"248","author":"H Ikeda","year":"1998","unstructured":"Ikeda, H. et al. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochemical and biophysical research communications 248, 436\u2013440, https:\/\/doi.org\/10.1006\/bbrc.1998.8983 (1998).","journal-title":"Biochemical and biophysical research communications"},{"key":"26531_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1006\/bbrc.2000.3634","volume":"277","author":"M Yanase","year":"2000","unstructured":"Yanase, M. et al. Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochemical and biophysical research communications 277, 72\u201378, https:\/\/doi.org\/10.1006\/bbrc.2000.3634 (2000).","journal-title":"Biochemical and biophysical research communications"},{"key":"26531_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0006-291X(03)00726-5","volume":"305","author":"M Yanase","year":"2003","unstructured":"Yanase, M. et al. Functional diversity between Rho-kinase- and MLCK-mediated cytoskeletal actions in a myofibroblast-like hepatic stellate cell line. Biochemical and biophysical research communications 305, 223\u2013228 (2003).","journal-title":"Biochemical and biophysical research communications"},{"key":"26531_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep46705","volume":"7","author":"T Yamazaki","year":"2017","unstructured":"Yamazaki, T. et al. Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Scientific reports 7, 46705, https:\/\/doi.org\/10.1038\/srep46705 (2017).","journal-title":"Scientific reports"},{"key":"26531_CR37","doi-asserted-by":"publisher","first-page":"e103532","DOI":"10.1371\/journal.pone.0103532","volume":"9","author":"T Pleli","year":"2014","unstructured":"Pleli, T. et al. Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis\u2013a prospective cohort study. PloS one 9, e103532, https:\/\/doi.org\/10.1371\/journal.pone.0103532 (2014).","journal-title":"PloS one"},{"key":"26531_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cca.2014.03.006","volume":"433","author":"M Kondo","year":"2014","unstructured":"Kondo, M. et al. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma. Clinica chimica acta; international journal of clinical chemistry 433, 128\u2013134, https:\/\/doi.org\/10.1016\/j.cca.2014.03.006 (2014).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"26531_CR39","doi-asserted-by":"crossref","unstructured":"Joshita, S. et al. Serum Autotaxin Is a Useful Liver Fibrosis Marker in Patients with Chronic Hepatitis B Virus Infection. Hepatology research: the official journal of the Japan Society of Hepatology (2017 in press).","DOI":"10.1111\/hepr.12997"},{"key":"26531_CR40","doi-asserted-by":"publisher","unstructured":"Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1008\u20131018, 1018 e1001, https:\/\/doi.org\/10.1053\/j.gastro.2010.05.009 (2010).","DOI":"10.1053\/j.gastro.2010.05.009"},{"key":"26531_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep30847","volume":"6","author":"E Wunsch","year":"2016","unstructured":"Wunsch, E. et al. Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic LiverDiseases. Scientific reports 6, 30847, https:\/\/doi.org\/10.1038\/srep30847 (2016).","journal-title":"Scientific reports"},{"key":"26531_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","volume":"60","author":"Y Nakanuma","year":"2010","unstructured":"Nakanuma, Y. et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathology international 60, 167\u2013174, https:\/\/doi.org\/10.1111\/j.1440-1827.2009.02500.x (2010).","journal-title":"Pathology international"},{"key":"26531_CR43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1177\/003591576706001205","volume":"60","author":"P Scheuer","year":"1967","unstructured":"Scheuer, P. Primary biliary cirrhosis. Proceedings of the Royal Society of Medicine 60, 1257\u20131260 (1967).","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"26531_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares, A., Caballeria, L. & Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130, 715\u2013720, https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029 (2006).","journal-title":"Gastroenterology"},{"key":"26531_CR45","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi, T. et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. The American journal of gastroenterology 105, 2186\u20132194, https:\/\/doi.org\/10.1038\/ajg.2010.216 (2010).","journal-title":"The American journal of gastroenterology"},{"key":"26531_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","volume":"41","author":"N Azemoto","year":"2011","unstructured":"Azemoto, N. et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatology research: the official journal of the Japan Society of Hepatology 41, 310\u2013317, https:\/\/doi.org\/10.1111\/j.1872-034X.2011.00782.x (2011).","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"key":"26531_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2007.10.005","volume":"388","author":"K Nakamura","year":"2008","unstructured":"Nakamura, K. et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clinica chimica acta; international journal of clinical chemistry 388, 51\u201358, https:\/\/doi.org\/10.1016\/j.cca.2007.10.005 (2008).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"26531_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/hepr.12997","volume":"48","author":"S Joshita","year":"2018","unstructured":"Joshita, S. et al. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatology research: the official journal of the Japan Society of Hepatology 48, 275\u2013285, https:\/\/doi.org\/10.1111\/hepr.12997 (2018).","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"key":"26531_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. The New England journal of medicine 375, 631\u2013643, https:\/\/doi.org\/10.1056\/NEJMoa1509840 (2016).","journal-title":"The New England journal of medicine"},{"key":"26531_CR50","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/hep.21172","volume":"43","author":"J Wesierska-Gadek","year":"2006","unstructured":"Wesierska-Gadek, J. et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology (Baltimore, Md.) 43, 1135\u20131144, https:\/\/doi.org\/10.1002\/hep.21172 (2006).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR51","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/infdis\/jiw372","volume":"214","author":"L Kostadinova","year":"2016","unstructured":"Kostadinova, L. et al. During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy. The Journal of infectious diseases 214, 1438\u20131448, https:\/\/doi.org\/10.1093\/infdis\/jiw372 (2016).","journal-title":"The Journal of infectious diseases"},{"key":"26531_CR52","doi-asserted-by":"publisher","first-page":"e0195632","DOI":"10.1371\/journal.pone.0195632","volume":"13","author":"T Yamazaki","year":"2018","unstructured":"Yamazaki, T. et al. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PloS one 13, e0195632, https:\/\/doi.org\/10.1371\/journal.pone.0195632 (2018).","journal-title":"PloS one"},{"key":"26531_CR53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jhep.2017.01.009","volume":"66","author":"MJ Farquhar","year":"2017","unstructured":"Farquhar, M. J. et al. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. Journal of hepatology 66, 919\u2013929, https:\/\/doi.org\/10.1016\/j.jhep.2017.01.009 (2017).","journal-title":"Journal of hepatology"},{"key":"26531_CR54","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 38, 518\u2013526, https:\/\/doi.org\/10.1053\/jhep.2003.50346 (2003).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"26531_CR55","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/hep.21700","volume":"46","author":"T Umemura","year":"2007","unstructured":"Umemura, T. et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology (Baltimore, Md.) 46, 463\u2013471, https:\/\/doi.org\/10.1002\/hep.21700 (2007).","journal-title":"Hepatology (Baltimore, Md.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26531-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:43:30Z","timestamp":1671601410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26531-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26531"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26531-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"26 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Koji Igarashi and Gary L. Norman are employees of TOSOH Corporation and Inova Diagnostics, respectively. The remaining authors declare that they have nothing to disclose regarding funding from industries or other conflicts of interest with respect to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8159"}}